This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license. This work is licensed under a Creative Commons ...

1Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. 2Department of Radiation Oncology, Harbin Medical University Cancer Hospital, Harbin, ...

Purpose: Cancer-associated fibroblasts (CAFs) are highly heterogeneous in pancreatic ductal adenocarcinoma (PDAC). We previously reported that CAFs can acquire an endothelial phenotype under stress.

Cancer Res (2023) 83 (8_Supplement): LB320. QTX3034 has good solubility, permeability, and moderate protein binding in human plasma. The systemic clearance in rats and dogs was moderate to high, ...

Findings from a phase I/II trial provide clinical proof-of-concept for a first-in-class mRNA-encoded T-cell engager targeting CLDN6 and CD3. Produced in vivo, the bispecific was well tolerated and had ...

Radiation Research Program, Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland. *Corresponding Author: Jeffrey C. Buchsbaum, Radiation Research Program, Division of Cancer Treatment ...

*Corresponding Author: Mara H. Sherman, Cancer Biology & Genetics, Memorial Sloan Kettering Cancer Center, 417 East 68th Street, 1261, New York, NY 10065. E-mail: [email protected] ...

Drug companies are pouring billions of dollars into PD-1×VEGF bispecific antibodies, hoping these dual-action drugs can outperform existing immunotherapy and anti-angiogenic combinations in lung ...

1Department of Population Health Sciences, Weill Cornell Medicine, New York, New York. 2Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, New York. *Corresponding Author: Kevin ...

Cancer Res (2024) 84 (6_Supplement): 973. Addition of ENZ or AAP to androgen deprivation therapy (ADT) as first-line treatment for advanced prostate cancer improves survival compared to ADT alone.